Risankizumab effective in Moderate-to-Severe Plaque Psoriasis with favourable safety profile

The data for this integrated safety analysis came from 17 completed or ongoing clinical trials of risankizumab for moderate-to-severe psoriasis. The results showed that the event rates for adverse events (AEs) and AEs of safety interest were consistent with risankizumab's known safety profile, confirming its suitability for long-term use.

In this integrated analysis, the treatment-emergent mortality rate was 0.5 percent (16 deaths, 0.2 E/100 PY), with a standardized mortality ratio for treatment-emergent deaths of 0.32 (95 percent CI, 0.18– 0.53), indicating that the risk of mortality was not increased in risankizumab-treated patients when compared to the general population. The EAER of adjudicated MACE in this integrated analysis of risankizumab studies was low in both analysis sets (0.2 and 0.3 E/100 PY in the short- and long-term analysis sets, respectively), and compares favorably with the range in the PSOLAR study for other biologic therapies.

In conclusion, this comprehensive analysis of over 7000 PY of risankizumab exposure supports risankizumab's favorable safety profile in patients with moderate-to-severe psoriasis. Indeed, these findings do not point to any new potential risankizumab safety signals. These reassuring findings should help practitioners make long-term treatment decisions for their patients with moderate-to-severe psoriasis.

Reference:

Gordon, K. B., Lebwohl, M., Papp, K. A., Bachelez, H., Wu, J. J., Langley, R. G., Blauvelt, A., Kaplan, B., Shah, M., Zhao, Y., Sinvhal, R., & Reich, K. (2021). Long‐Term Safety of Risankizumab From 17 Clinical Trials in Patients With Moderate‐to‐Severe Plaque Psoriasis. In British Journal of Dermatology. Wiley. https://doi.org/10.1111/bjd.20818